Evidence map›Paper›PMID 42492483›Full record

ArticleBritish journal of pharmacology2026

Cannabinoid CB

Ifeoluwa D Solomon, Sumanta Garai, Ganesh A Thakur, Andrea G Hohmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ifeoluwa D SolomonDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, USA.
Sumanta GaraiCenter for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Ganesh A ThakurCenter for Drug Discovery, Northeastern University, Boston, Massachusetts, USA.
Andrea G HohmannDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana, USA.ORCID https://orcid.org/0000-0003-0941-6435

Funding

Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · 1994 to 2025
$9.9M
Development of non-opioid, non-addictive analgesics for treating neuropathic painR01NS137079 · NORTHEASTERN UNIVERSITY · 2025 to 2025
$675k
CB2 Cannabinoid Mechanisms for Suppressing Opioid Tolerance and DependenceR01DA047858 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI Andrea Grace Hohmann, Kenneth Mackie · 2022 to 2022
$517k
NEI NIH HHS EY024717NEI NIH HHS R01 EY024717NIDA NIH HHS DA009158NIDA NIH HHS DA047858NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA047858NINDS NIH HHS NS137079NINDS NIH HHS R01 NS137079Sharon Brehem Fellowship
6 · The paper itself

Abstract

background and purposePositive allosteric modulators (PAMs) engage sites distinct from the orthosteric CB EXPERIMENTAL APPROACH: We evaluated therapeutic efficacy of the pure CB KEY

resultsGAT228 and GAT229 attenuated CFA-induced mechanical hypersensitivity in a CB CONCLUSION AND IMPLICATION: CB

Indexed as

allosteric agonistdespairendocannabinoidinflammatory painmemory deficitmotor impairmentpositive allosteric modulatorrespiratory depressiontolerance

Identifiers

PMID42492483
PMCPMC13404072

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.